Teva’s Generic Irbesartan Deserves 180-Day Exclusivity Because Of Review Delays, FDA Says

Lupin Pharmaceuticals had filed a citizen petition arguing that Teva was not entitled to the first-mover 180-day exclusivity because it failed to get tentative approval within 30 months, but FDA said that it had changed its criteria and requested additional testing.